Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2/3 1Phase 2 1

Status

Recruiting 2Completed 2Unknown 1Terminated 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Clinical Stage I Gastric Cancer AJCC v8 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Lymph Node Excision × Clear all
NCT05836584 2026-05-28

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
240 enrolled
Gastrointestinal

Clinical Stage I Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡